US FDA approves BridgeBio's drug for rare heart condition
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
Charles Schwab Investment Management Inc. Buys 16,756 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Charles Schwab Investment Management Inc. increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – ...
PNC Financial Services Group Inc. Increases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
PNC Financial Services Group Inc. boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 1.2% in ...
Nasdaq5d
This Is What Whales Are Betting On Alnylam Pharmaceuticals
Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ:ALNY) revealed 11 unusual trades. Delving into ...
BioPharma Dive2d
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
Le Lézard1h
Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper ...
Le Lézard1h
Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting
Rakovina Therapeutics Inc. ("Rakovina" or the "Company"), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, announces ...
Alnylam Pharma’s Promising TTR RNAi Program and Strategic Advancements Drive Buy Rating with $400 Price Target
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a ...
Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
Investing6d
Alnylam stock holds price target and buy rating on promising drug data
On Tuesday, H.C. Wainwright maintained a Buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), with a consistent price target of $400.00. This endorsement follows the presentation of ...
Investing5d
Alnylam stock holds price target and buy rating on promising drug data
On Tuesday, H.C. Wainwright maintained a Buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), with a consistent price target of $400.00. This endorsement follows the presentation of ...